Novartis Likely to Confirm Guidance -- Market Talk

Dow Jones04-02 16:01

0801 GMT - Novartis is likely to confirm its 2026 guidance when it reports first-quarter results later this month, J.P. Morgan analysts say in a research note. The Swiss drugmaker likely had a solid first quarter, even though the loss of U.S. sales from the Entresto heart drug due to generic competition and favorable pricing trends in the year-earlier period should weigh on sales, JPM says. The analysts estimate Novartis's first-quarter sales at $13.56 billion, core operating profit at $5.15 billion and core EPS at $2.10. Novartis guided for 2026 sales growth in the low-single-digit percentage range and core operating profit to decline by a low single digit when excluding currency changes, an outlook JPM expects to be reiterated. Shares are flat at 122.90 Swiss francs. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

April 02, 2026 04:01 ET (08:01 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624579698?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-02 16:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624579698","market":"sh","top_or_hot":-1,"title":"Novartis Likely to Confirm Guidance -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0801 GMT - Novartis is likely to confirm its 2026 guidance when it reports first-quarter results later this month, J.P. Morgan analysts say in a research note. The Swiss drugmaker likely had a solid first quarter, even though the loss of U.S. sales from the Entresto heart drug due to generic competition and favorable pricing trends in the year-earlier period should weigh on sales, <a href=\"https://laohu8.com/S/JPM\">JPM</a> says. The analysts estimate Novartis's first-quarter sales at $13.56 billion, core operating profit at $5.15 billion and core EPS at $2.10. Novartis guided for 2026 sales growth in the low-single-digit percentage range and core operating profit to decline by a low single digit when excluding currency changes, an outlook JPM expects to be reiterated. Shares are flat at 122.90 Swiss francs. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 02, 2026 04:01 ET (08:01 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Likely to Confirm Guidance -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Likely to Confirm Guidance -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-02 16:01</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0801 GMT - Novartis is likely to confirm its 2026 guidance when it reports first-quarter results later this month, J.P. Morgan analysts say in a research note. The Swiss drugmaker likely had a solid first quarter, even though the loss of U.S. sales from the Entresto heart drug due to generic competition and favorable pricing trends in the year-earlier period should weigh on sales, <a href=\"https://laohu8.com/S/JPM\">JPM</a> says. The analysts estimate Novartis's first-quarter sales at $13.56 billion, core operating profit at $5.15 billion and core EPS at $2.10. Novartis guided for 2026 sales growth in the low-single-digit percentage range and core operating profit to decline by a low single digit when excluding currency changes, an outlook JPM expects to be reiterated. Shares are flat at 122.90 Swiss francs. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 02, 2026 04:01 ET (08:01 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0009355771.USD","symbol_name":"骏利亨德森环球生命科技A Acc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2624579698","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624579698","pubTimestamp":1775116860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0801 GMT - Novartis is likely to confirm its 2026 guidance when it reports first-quarter results later this month, J.P. Morgan analysts say in a research note. The Swiss drugmaker likely had a solid first quarter, even though the loss of U.S. sales from the Entresto heart drug due to generic competition and favorable pricing trends in the year-earlier period should weigh on sales, JPM says. The analysts estimate Novartis's first-quarter sales at $13.56 billion, core operating profit at $5.15 billion and core EPS at $2.10. Novartis guided for 2026 sales growth in the low-single-digit percentage range and core operating profit to decline by a low single digit when excluding currency changes, an outlook JPM expects to be reiterated. Shares are flat at 122.90 Swiss francs. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","BK4007":"制药","BK4585":"ETF&股票定投概念","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4588":"碎股","BK4578":"CAR-T","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4532":"文艺复兴科技持仓","NVS":"诺华"},"translate_title":"诺华可能会确认指引——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9},"content_text":"0801 GMT - Novartis is likely to confirm its 2026 guidance when it reports first-quarter results later this month, J.P. Morgan analysts say in a research note. The Swiss drugmaker likely had a solid first quarter, even though the loss of U.S. sales from the Entresto heart drug due to generic competition and favorable pricing trends in the year-earlier period should weigh on sales, JPM says. The analysts estimate Novartis's first-quarter sales at $13.56 billion, core operating profit at $5.15 billion and core EPS at $2.10. Novartis guided for 2026 sales growth in the low-single-digit percentage range and core operating profit to decline by a low single digit when excluding currency changes, an outlook JPM expects to be reiterated. Shares are flat at 122.90 Swiss francs. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2026 04:01 ET (08:01 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624579698","isCrawlerRequest":true}